CBD Life Sciences Inc.’s (OTC:CBDL) stock surges 10%: What’s the Buzz?

The CBD industry has grown at a remarkable rate in recent times, and CBD Life Sciences Inc. (OTC:CBDL) is one of the leading players in that space at this point.

CBD Life Sciences Inc. (CBDL) Ignites Expanding Revenue Stream With RangeMe, Poised for Explosive Growth

Yesterday the company announced that it affected a major strategic breakthrough through the expansion of its revenue channels. CBD Life Sciences achieved that through a partnership with RangeMe, a platform for premium category product discovery and sourcing. The news came as a source of considerable optimism for investors, and the CBD Life Sciences stock jumped by 10% as a consequence. It may be a good idea to take a closer look at the implications of the partnership.

RangeMe boasts of more than 200000 retail buyers, and that includes some of the major global retailers. As a result, the partnership would provide CBD Life Sciences with the basis for potentially massive growth and further reinforcing its position as a leading player in the CBD space.

The consumer demand for CBD products has been going up steadily, and CBD Life Sciences is in the best position to grab the opportunity, the company noted in the news release. The company also announced yesterday that since February it had generated growth of 1405.46%. The partnership with RangeMe could be the push that the company would need for further growth.

Management Comment

“This is just the beginning,” said Lisa Nelson, President and CEO of CBD Life Sciences Inc. “We’ve already achieved an unprecedented 1405.46% revenue growth since February, and by tapping into the power of RangeMe, we’re positioning ourselves for explosive results. Our investors have never been more excited, and for good reason—we’re on the cusp of something huge.”